The present invention is related to enhancing the function of anti-tumor antibodies by regulating Fc.gamma.RIIB-mediated activity. In particular, disrupting SHIP activation by Fc.gamma.RIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to Fc.gamma.RIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting Fc.gamma.RIIB molecule is a potent regulator of cytotoxicity in vivo.

 
Web www.patentalert.com

< PT32 sperm protein, sperm c-Yes, oocyte cytoplasmic c-Yes, and uses thereof

> Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections

~ 00457